KK4277 / SBI Biotech, Kyowa Kirin - LARVOL DELTA

Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277 (ACR Convergence 2025) - P1 | "Multiple doses of 100 mg/body IV were tolerable. KK4277 greatly depleted pDC in blood and skin and reduced type I IFN. A proof of pharmacological action was obtained."

Clinical • First-in-human • P1 data • PK/PD data • Cutaneous Lupus Erythematosus • Immunology • Inflammation • Inflammatory Arthritis • Lupus

A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus (clinicaltrials.gov) - P1 | N=157 | Active, not recruiting | Sponsor: Kyowa Kirin Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus (clinicaltrials.gov) - P1 | N=157 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd. | N=116 ➔ 157 | Trial completion date: Mar 2025 ➔ Dec 2025

Enrollment change • Trial completion date • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus (clinicaltrials.gov) - P1 | N=116 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2024 ➔ Mar 2025 | Trial primary completion date: Sep 2023 ➔ Dec 2024

Enrollment open • Trial completion date • Trial primary completion date • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Newly added pipeline product: SBI-9674 (SBI Biotech Press Release)

Pipeline update • Lupus